Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Core Insights - Ernexa Therapeutics is advancing its lead program, ERNA-101, which is a synthetic, off-the-shelf cell therapy aimed at treating advanced ovarian cancer by activating and regulating the immune system [1][6] - The company will present preclinical data at the AACR Special Conference, highlighting the potential of engineered iPSC-derived MSCs to reshape the tumor microenvironment in ovarian cancer [2][3] - The presentation will be made by Dr. Michael Andreeff, a leading expert in cell therapy, emphasizing the importance of this research in expanding treatment options for patients [2][3] Company Overview - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5][6] - The company's technology allows for scalable, allogeneic treatment solutions without the need for patient-specific cell harvesting [5] - ERNA-201 is another product aimed at treating inflammation and autoimmune diseases, but the primary focus remains on ERNA-101 for ovarian cancer [6] Upcoming Events - The oral presentation titled "Gene-modified iPS-derived MSC restore a 'Hot' immune microenvironment in high-grade serous ovarian cancer" is scheduled for September 20, 2025, at the Grand Hyatt Denver Hotel [8]